You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
魯抗醫藥(600789.SH):“鹽酸林可黴素硫酸大觀黴素預混劑”獲批上市
格隆匯 06-11 17:24

格隆匯6月11日丨魯抗醫藥(600789.SH)公吿,近日,公司全資子公司山東魯抗舍裏樂藥業有限公司高新區分公司收到農業農村部審批簽發的鹽酸林可黴素硫酸大觀黴素預混劑獸藥產品批准文號。該產品通用名稱為鹽酸林可黴素硫酸大觀黴素預混劑。

鹽酸林可黴素為林可胺類抗生素,主要抗革蘭陽性菌,硫酸大觀黴素為氨基糖苷類抗生素,主要抗革蘭陰性菌,兩者聯用可從不同環節阻礙細菌蛋白質的合成,具有較好的協同作用,用於防治豬赤痢、沙門氏菌病、大腸桿菌性腸炎及支原體肺炎,尤其對豬最常見的兩種條件性傳染病——黴形體性肺炎和豬大腸桿菌病的混合感染治療效果明顯。

本次全資子公司獲得鹽酸林可黴素硫酸大觀黴素預混劑獸藥產品批准文號為國內首個原研藥仿製產品,將進一步豐富公司獸用藥產品線和產品結構,對提升公司市場競爭力、推動公司動物用藥領域戰略佈局的實施具有積極的促進作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account